Amgen Lines Up Biosimilar Launches For Early 2025

As Firm Reports Q2 Results That See Downturns For Bevacizumab And Adalimumab

 
• By Dave Wallace
  
2025 with stopwatch as zero
Amgen is counting down to a pair of key launches in Q1 2025 • Source: Shutterstock

More from Biosimilars

More from Products